Table 1.
Patient characteristics enrolled in this trial
| Total | S-1 + vaccine | S-1 | |||
| n = 14 | n = 6 | n = 8 | |||
| Age (years) | 58.5 (40–71) | 61.5 (54–71) | 55 (40–71) | ||
| Gender (Male/Female) | 11/3 | 6/0 | 5/3 | ||
| Performance Status (0/1) | 0/14 | 0/6 | 0/8 | ||
| HLA-A*2402 (+/–) | 7/7 | 6/0 | 1/7 | ||
| Surgery (Total/Partial) | 5/9 | 3/3 | 2/6 | ||
| pStage (IIIA/IIIB/IIIC) | 5/7/2 | 1/3/2 | 4/4/0 | ||
| pT stage (T2/T3/T4a/T4b) | 1/10/2/1 | 0/3/2/1 | 1/7/0/0 | ||
| pN stage(N0/N1/N2/N3a/N3b) | 1/0/4/6/3 | 1/0/1/2/2 | 0/0/3/4/1 | ||
| Number of LN metastasis | 7 (0–32) | 11 (0–23) | 7 (4–32) |
HLA, human leukocyte antigen; LN, lymph node; pN, pathological Nodal stage; pStage, pathological Stage; pT, pathological T stage.